68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours
R Sharma, WM Wang, S Yusuf, J Evans…�- Radiotherapy and�…, 2019 - Elsevier
Purpose [177 Lu] DOTATATE prolongs progression free survival (PFS) in metastatic
neuroendocrine tumours (NETs). However, objective response rate is low. This, coupled
with long duration of therapy and expense suggest need for better selection. We aim to
assess whether baseline [68 Ga] DOTATATE-PET/CT parameters, and whether response
assessment by PET accurately predicts clinical outcome to [177 Lu] DOTATATE.
Experimental design Retrospective study of patients receiving [177 Lu] DOTATATE was�…
neuroendocrine tumours (NETs). However, objective response rate is low. This, coupled
with long duration of therapy and expense suggest need for better selection. We aim to
assess whether baseline [68 Ga] DOTATATE-PET/CT parameters, and whether response
assessment by PET accurately predicts clinical outcome to [177 Lu] DOTATATE.
Experimental design Retrospective study of patients receiving [177 Lu] DOTATATE was�…